文献速递淋巴瘤白血病

抗CD19嵌合抗原受体T细胞疗法的长期随访

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
PubMed 文献 · J Clin Oncol · 2020-10-06

该研究报告了43例复发B细胞恶性肿瘤患者接受46次抗CD19 CAR T细胞治疗后的长期结局,中位无事件生存期为55个月,51%的可评估治疗获得超过3年的缓解持续时间,长期不良事件除B细胞耗竭和低丙种球蛋白血症外罕见。

要点

  • 51%的可评估治疗获得>3年缓解持续时间,最长缓解持续9年。
  • 中位无事件生存期为55个月。
  • 长期不良事件除B细胞耗竭和低丙种球蛋白血症外罕见。

核心结论

  • 51%的可评估抗CD19 CAR T细胞治疗获得持续≥3年的完全缓解,最长缓解持续9年,晚期不良事件罕见。

研究设计与样本

  • 2009年至2015年间,43例复发B细胞恶性肿瘤患者接受了46次CAR T细胞治疗(NCT00924326)。
  • 患者类型包括弥漫大B细胞淋巴瘤或原发纵隔B细胞淋巴瘤(n=28)、低级别B细胞淋巴瘤(n=8)和慢性淋巴细胞白血病(n=7)。
  • 使用的CAR为FMC63-28Z,预处理方案为环磷酰胺联合氟达拉滨。

主要发现

  • 所有可评估治疗中,缓解持续时间>3年的比例为51%(95% CI,35%至67%)。
  • DLBCL/PMBCL组>3年缓解持续时间为48%(95% CI,28%至69%),低级别淋巴瘤组为63%(95% CI,25%至92%),CLL组为50%(95% CI,16%至84%)。
  • 45次可评估治疗的中位无事件生存期为55个月。

临床怎么用

  • 抗CD19 CAR T细胞治疗可使部分复发B细胞恶性肿瘤患者获得长期缓解,需关注B细胞耗竭和低丙种球蛋白血症等长期不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Anti-CD19 chimeric antigen receptors (CARs) are artificial fusion proteins that cause CD19-specific T-cell activation. Durability of remissions and incidence of long-term adverse events are critical factors determining the utility of anti-CD19 CAR T-cell therapy, but long-term follow-up of patients treated with anti-CD19 CAR T cells is limited. This work provides the longest follow-up of patients in remission after anti-CD19 CAR T-cell therapy. METHODS: Between 2009 and 2015, we administered 46 CAR T-cell treatments to 43 patients (ClinicalTrials.gov identifier: NCT00924326). Patients had relapsed B-cell malignancies of the following types: diffuse large B-cell lymphoma or primary mediastinal B-cell lymphoma (DLBCL/PMBCL; n = 28), low-grade B-cell lymphoma (n = 8), or chronic lymphocytic leukemia (CLL; n = 7). This report focuses on long-term outcomes of these patients. The CAR used was FMC63-28Z; axicabtagene ciloleucel uses the same CAR. Cyclophosphamide plus fludarabine conditioning chemotherapy was administered before CAR T cells. RESULTS: The percentages of CAR T-cell treatments resulting in a > 3-year duration of response (DOR) were 51% (95% CI, 35% to 67%) for all evaluable treatments, 48% (95% CI, 28% to 69%) for DLBCL/PMBCL, 63% (95% CI, 25% to 92%) for low-grade lymphoma, and 50% (95% CI, 16% to 84%) for CLL. The median event-free survival of all 45 evaluable treatments was 55 months. Long-term adverse effects were rare, except for B-cell depletion and hypogammaglobulinemia. Median peak blood CAR-positive cell levels were higher among patients with a DOR of > 3 years (98/µL; range, 9-1,217/µL) than among patients with a DOR of < 3 years (18/µL; range, 0-308/μL, P = .0051). CONCLUSION: Complete remissions of a variety of B-cell malignancies lasting ≥ 3 years occurred after 51% of evaluable anti-CD19 CAR T-cell treatments. Remissions of up to 9 years are ongoing. Late adverse events were rare.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cappell KM, Sherry RM, Yang JC, et al. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020. PMID: 33021872. doi:10.1200/JCO.20.01467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。